VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the
development and commercialization of novel therapeutic products, today
announced that Peter Tam, chief operating officer, will present an
overview of the company at the 29th Annual Cowen and Company
Healthcare Conference.
The VIVUS presentation will take place at the Boston Marriott Copley
Place on Thursday, March 19, 2009 at 10:20 a.m. ET. A live webcast and
30-day archive of the presentation will be available at http://www.vivus.com
or http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=VVUS&item_id=2088424.
About VIVUS
VIVUS is a biopharmaceutical company developing innovative,
next-generation therapies to address unmet needs in obesity, diabetes
and sexual health. The company's lead investigational product in
clinical development, Qnexa™, is expected to complete Phase 3 clinical
trials for the treatment of obesity in 2009. Qnexa is also in Phase 2
clinical development for the treatment of type 2 diabetes. In the area
of sexual health, VIVUS is in Phase 3 development with avanafil, its
PDE5 inhibitor drug candidate, and in Phase 2 development of Luramist™,
its drug candidate for the treatment of hypoactive sexual desire
disorder (HSDD) in women. MUSE® (alprostadil), a first generation
therapy for the treatment of ED, is already on the market and generating
revenue for VIVUS. For more information about the company, please visit www.vivus.com.
VIVUS, Inc.
Timothy E. Morris, 650-934-5200
Chief
Financial Officer
or
Investor Relations:
The
Trout Group
Brian Korb, 646-378-2923
or
Media
Relations:
Pure Communications, Inc.
Sheryl Seapy,
949-608-0841
